We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 3

Figure 3. Cathelicidins Mediate Changes in Lung Cytokine Concentrations Following Influenza Virus Infection.. From: Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37.

Groups of 5 mice were infected with 10 MLD50 of A/PR/8/34 influenza virus via intranasal administration on day 0. Mice were nebulized with 200 µl of saline (control), or LL-37 peptide (500 µg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and concentration of the indicated cytokines in the bronchoalveolar lavage (BAL) fluid were measured by BioPlex assay. Figures show mean values ± SEM. Statistical analysis was performed using an two-way analysis of variance (ANOVA) (*P≤0.05).

Peter G. Barlow, et al. PLoS One. 2011;6(10):e25333.
2.
Figure 4

Figure 4. Cathelicidins show antiviral activity against influenza virus in vitro.. From: Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37.

Influenza virus was pre-incubated with cathelicidin peptide or control peptide scrambled LL-37 (sLL-37) (A) at a range of concentrations as indicated for 1 hour at room temperature and a plaque formation assay was then performed to assess virus titer in MDCK-L cells in the presence of trypsin. Viruses used were A/PR/8/34 (H1N1) (A, B) or A/Udorn/307/72 (C). The antiviral activity of the cathelicidins LL-37 (A, C), mCRAMP (B) and Protegrin-1 (B) was assessed. Figures are representative of at least three independent experiments. Figures show mean values ± SEM. Statistical analysis was performed using an unpaired t-test to compare virus only titer with virus + peptide (*P≤0.05, ** P≤0.01).

Peter G. Barlow, et al. PLoS One. 2011;6(10):e25333.
3.
Figure 5

Figure 5. D-Isomer cathelicidins inhibit influenza virus.. From: Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37.

(A,B) Groups of 5 mice were infected with 10 MLD50 of A/PR/8/34 influenza virus via intranasal administration on day 0. Mice were nebulized with 200 µl of saline (control), zanamivir (500 µg/ml), D-LL-37 peptide (500 µg/ml) or D-mCRAMP peptide (500 µg/ml) once daily from day -1 to day 7. Mouse weight and survival was monitored daily up to 14 days post infection. Data represent mean values ± SEM from n = 1 experiment. Statistical analysis was performed using Kaplan Meier with a Mantel-Cox (log rank) test. Survival curves obtained with Zanamivir, D-LL-37 and D-mCRAMP treatments were significantly different (P≤0.001) compared to saline control treatment. (C) Groups of 5 mice were infected with 10MLD50 of A/PR/8/34 virus via intranasal administration on day 0. Mice were nebulized with 200 µl of saline (control), zanamivir (500 µg/ml), D-LL-37 peptide (500 µg/ml) or D-mCRAMP peptide (500 µg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and viral titer in the lungs was assessed by plaque assay. Figure is representative of n = 3 independent experiments. Figure shows mean values ± SEM. Statistical analysis was performed using an unpaired t-test to compare virus infected animals with virus/peptide and virus/zanamivir treated animals (*P≤0.05). (D) The antiviral activity of the cathelicidins D-LL-37 and D-mCRAMP was assessed. Figure is representative of n = 3 independent experiments. Figure shows mean values ± SEM. Statistical analysis was performed using an unpaired t-test to compare PR/8 only titer with PR/8 + Peptide (*P≤0.05, ** P≤0.01).

Peter G. Barlow, et al. PLoS One. 2011;6(10):e25333.
4.
Figure 2

Figure 2. Cathelicidins Show Species-Specific Antiviral Effects.. From: Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37.

(A,B,D,E) Groups of 5 mice were infected with 10 MLD50 of A/PR/8/34 influenza virus via intranasal administration on day 0. Mice were nebulized with 200 µl of saline (control), zanamivir (500 µg/ml), the murine cathelicidin mCRAMP (500 µg/ml) (A and B) or the porcine cathelicidin Protegrin-1 (500 µg/ml) (D and E) once daily from day -1 to day 7. Mouse body weight (A, D) and survival (B, E) was monitored daily up to 14 days post infection. Data represent mean values ± SEM, for three independent experiments (A and B) or one experiment (D and E). Statistical analysis was performed using Kaplan Meier with a Mantel-Cox (log rank) test. Survival curves obtained with Zanamivir and mCRAMP treatments were significantly different (P≤0.001) compared to saline control treatment. There was no difference between saline treated and Protegrin treated groups. (C, F) Groups of three mice were infected with 10 MLD50 of A/PR/8/34 virus via intranasal administration on day 0. Mice were nebulized with 200 µl of saline (control), zanamivir (500 µg/ml), the murine cathelicidin mCRAMP (500 µg/ml) or the porcine cathelicidin Protegrin-1 (500 µg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and viral titer in the lungs was assessed by plaque assay. Figure shows mean values ± SEM. Statistical analysis was performed using an unpaired t-test to compare virus infected animals with virus/peptide and virus/zanamivir treated animals (*P≤0.05, **P≤0.01, ***P≤0.001).

Peter G. Barlow, et al. PLoS One. 2011;6(10):e25333.
5.
Figure 1

Figure 1. LL-37 Protects Mice Against Influenza Virus Disease.. From: Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37.

(A,B) Groups of 5 mice were inoculated with 10 MLD50 of A/Puerto Rico/8/1934 influenza virus by the intranasal route on day 0. Mice were nebulized with 200 µl of saline (control), zanamivir (500 µg/ml), LL-37 peptide (500 µg/ml) or scrambled LL-37 control peptide (500 µg/ml) once daily from day -1 to day 7. Mouse body weight (A) and survival (B) was monitored daily up to 14 days post infection. Data represent mean values ± SEM, for three independent experiments. Statistical analysis was performed using Kaplan Meier with a Mantel-Cox (log rank) test. Survival curves obtained with Zanamivir and LL-37 treatments were significantly different (P≤0.001) compared to saline control treatment. There was no difference between saline treated and sLL-37 treated groups. (C) Groups of three mice (Female, 6–8 week old Balb/c) were inoculated with 10 MLD50 of A/PR/8/34 virus intranasally on day 0. Mice were nebulized with 200 µl of saline (control) zanamivir (500 µg/ml), LL-37 peptide (500 µg/ml) or scrambled LL-37 control peptide (500 µg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and viral titer in the lungs was assessed by plaque assay. Figure is representative of three independent experiments. Figure shows mean values ± SEM. Statistical analysis was performed using a Student t-test to compare virus infected animals with virus/peptide and virus/zanamivir treated animals (*P≤0.05).

Peter G. Barlow, et al. PLoS One. 2011;6(10):e25333.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk